Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Total Debt (2016 - 2025)

Historic Total Debt for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $47.8 million.

  • Fortress Biotech's Total Debt fell 895.51% to $47.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.8 million, marking a year-over-year decrease of 895.51%. This contributed to the annual value of $58.0 million for FY2024, which is 475.55% down from last year.
  • Per Fortress Biotech's latest filing, its Total Debt stood at $47.8 million for Q3 2025, which was down 895.51% from $50.0 million recorded in Q2 2025.
  • Fortress Biotech's Total Debt's 5-year high stood at $91.7 million during Q4 2022, with a 5-year trough of $42.6 million in Q3 2021.
  • In the last 5 years, Fortress Biotech's Total Debt had a median value of $56.4 million in 2025 and averaged $62.0 million.
  • As far as peak fluctuations go, Fortress Biotech's Total Debt skyrocketed by 11415.82% in 2022, and later crashed by 4977.13% in 2023.
  • Fortress Biotech's Total Debt (Quarter) stood at $42.9 million in 2021, then surged by 113.64% to $91.7 million in 2022, then crashed by 33.66% to $60.9 million in 2023, then fell by 4.76% to $58.0 million in 2024, then decreased by 17.58% to $47.8 million in 2025.
  • Its Total Debt was $47.8 million in Q3 2025, compared to $50.0 million in Q2 2025 and $56.4 million in Q1 2025.